NOVEMBER 2024 SUPPLEMENTAL LINE OF CREDIT LETTER AGREEMENTSupplemental Line of Credit Agreement • November 14th, 2024 • Galectin Therapeutics Inc • Pharmaceutical preparations • Nevada
This letter agreement supplements that certain Line of Credit Agreement, dated as of July 25 2022, the (“Line of Credit Agreement”) and that certain Supplemental Line of Credit Letter Agreement, dated as of March 29, 2024, (the “Supplemental Line of Credit Agreement”) between Galectin Therapeutics, Inc., a Nevada corporation (the “Company”) and Richard E. Uihlein, an individual resident of the State of Illinois. This letter agreement (the “November 2024 Supplemental Line of Credit Agreement”) confirms Uihlein’s commitment to provide the Company with a line of credit of $6,000,000 (the “November 2024 Supplemental Line of Credit”), which is in addition to the $60,000,000 that was established under the Line of Credit Agreement and the $10,000,000 that was established under the Supplemental Line of Credit Agreement. The November 2024 Supplemental Line of Credit, subject to the restrictions outlined below, is available to finance the Company’s working capital needs in the amount of $6,000,0
